Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29335256 | 0.85 | SLC40A1 (0.54) | SLC22A12PTGES2SLC40A1TSHR | |
| SCHEMBL29335301 | 0.82 | SLC22A12 (0.47) | SLC22A12PTGES2SLC40A1CYP2D6 | |
| SCHEMBL29335255 | 0.82 | SLC40A1 (0.51) | PTGES2SLC40A1 | |
| SCHEMBL29335302 | 0.80 | PTGES2 (0.41) | MEN1KMT2AALDH1A1PTGES2SLC40A1 | |
| SCHEMBL29335298 | 0.79 | PTGES2 (0.47) | SLC22A12PTGES2SLC40A1 | |
| SCHEMBL3022491 | 0.78 | PTGES2 (0.52) | SLC22A12ALDH1A1PTGES2TSHR | |
| SCHEMBL29335303 | 0.78 | ACLY (0.39) | ALDH1A1PTGES2SLC40A1TSHR | |
| SCHEMBL29335290 | 0.77 | PTGES2 (0.47) | PTGES2TSHR | |
| SCHEMBL30897292 | 0.75 | PTGES2 (0.61) | PTGES2SLC40A1 | |
| SCHEMBL29335307 | 0.75 | SLC40A1 (0.43) | PTGES2SLC40A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | SLC22A12 2945/4885MEN1 2257/4885KMT2A 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.